Full Press Release Details
Allogene Therapeutics Presents Preclinical Findings Supporting ALLO-605, the First Anti-BCMA TurboCAR T Cell Therapy, at the 62nd Meeting of the American Society of Hematology.
ALLO
Allogene Therapeutics Presents Preclinical Findings Supporting ALLO-605, the First Anti-BCMA TurboCAR T Cell Therapy, at the 62nd Meeting of the American Society of Hematology
Key Takeaway: Allogene Therapeutics Presents Preclinical Findings Supporting ALLO-605, the First Anti-BCMA TurboCAR T Cell Therapy, at the 62nd Meeting of the American Society of Hematology